Neuropilin 1 (NRP1) Human shRNA Lentiviral Particle (Locus ID 8829)

Specifications

Product Data
Product Name	Neuropilin 1 (NRP1) Human shRNA Lentiviral Particle (Locus ID 8829)
Locus ID	8829
Synonyms	BDCA4; CD304; NP1; NRP; VEGF165R
Vector	pGFP-C-shLenti
Format	Lentiviral particles
RefSeq	BC007533, NM_001024628, NM_001024629, NM_001244972, NM_001244973, NM_003873, NR_045259, NM_001330068, NM_001024629.1, NM_001024629.2, NM_001024628.1, NM_001024628.2, NM_003873.1, NM_003873.2, NM_003873.3, NM_003873.4, NM_003873.5, NM_001244973.1, NM_001244972.1, BC007533.1, BC007737, BC007737.2, NM_003873.7
Summary	This gene encodes one of two neuropilins, which contain specific protein domains which allow them to participate in several different types of signaling pathways that control cell migration. Neuropilins contain a large N-terminal extracellular domain, made up of complement-binding, coagulation factor V/VIII, and meprin domains. These proteins also contains a short membrane-spanning domain and a small cytoplasmic domain. Neuropilins bind many ligands and various types of co-receptors; they affect cell survival, migration, and attraction. Some of the ligands and co-receptors bound by neuropilins are vascular endothelial growth factor (VEGF) and semaphorin family members. This protein has also been determined to act as a co-receptor for SARS-CoV-2 (which causes COVID-19) to infect host cells. [provided by RefSeq, Nov 2020]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.